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The rise in antibiotic-resistant microorganisms in recent years
has led to an increasing search for new antibiotics [11]. There-
fore, there is a prime need to discover new antimicrobial agents
to avert the emergence of resistance and ideally shorten the
duration of therapy.Among the essential pharmacophores reported for antimi-
crobial activity, the quinoline scaffold is still considered a via-
ble lead structure for the synthesis of more efﬁcacious and
broad spectrum antimicrobial agents [16]. The quinoline ring
has various activities, such as antimicrobial [3], antituberculo-
sis [7], antimalarial [13], anti-inﬂammatory [6], anticancer [1],
antibiotic [10], antihypertensive [12], tyrokinase PDGF-RTK
inhibiting agents [9], and antiHIV [21,19]. In addition, the re-
cent literature is enriched with progressive ﬁndings about the
synthesis and pharmacological activities of pyrazoline deriva-
tives. Pyrazolines have been found to possess antimicrobial
[22], antitubercular [18], anti-inﬂammatory [15], anti-tumor
[5] and antiviral activities [17].
On the other hand, being a valuable alternative to conven-
tional methods, syntheses of a variety of organic compounds
by microwave irradiation is gaining the attention of medicinal
chemists during the last decades [8,20]. Prompted by these
656 P.B. Miniyar et al.above observations and considering the signiﬁcant role of
quinoline and pyrazoline in biological applications, we wish
to report here the synthesis of a new series of quinolines–
pyrazoline derivatives and their anti-microbial activities.
2. Method
2.1. Experimental
Conventional method of synthesis has drawbacks of lower
yields and being time consuming. Here we have made attempts
to report novel chloroquinoline derivatives by combination of
both conventional as well as microwave irradiation method.
Purity of starting materials was conﬁrmed by TLC using
Merck silica gel precoated plate and with appropriate solvent
system. All the melting points were recorded on a Veego appa-
ratus and were uncorrected. IR spectra were recorded on Jasco
model 4100 FI-IR (KBr Pellet in the 4000-400 cm1 range).
The 1H NMR spectra were obtained at 300 MHz in CDCl3,
by using Varian instrument using TMS as internal standard
and chemical shift values are given in ppm downﬁeld to
TMS (tetramethylsilane). ESI-MS was recorded on a Micro-
mass Quattro II triple quadrupole mass spectrometer. The
starting material acetanilide (1a) was procured from commer-
cial source and p-bromo (1b) and p-nitro acetanilide (1c) were
prepared from acetanilide by standard procedure reported by
Furniss et al [23].
2.1.1. Step 1: synthesis of 2-chloroquinoline-3-carbaldehyde
derivatives (Meth-Cohn et al., 1981) [24]
Acetanilide derivatives, 1a–1c (13.5 g, 0.1 mol) were dissolved
in 33 ml of dimethyl formamide (0.25 mol) and to this solution
phosphorus oxychloride was added gradually at 0 C. The
reaction mixture was taken in a round bottom ﬂask (RBF)
equipped with reﬂux condenser and reﬂuxed for 5–6 h on oil
bath at 80–90 C. The solution was cooled to room tempera-
ture and then poured on 250 ml ice water. The precipitate
was collected by ﬁltration and recrystallized from ethyl acetate
to yield title compounds (2a–2c). Scheme of synthesis of
2-chloroquinoline-3-carbaldehyde derivatives is described in
Fig. 1 and their respective characterization data in Table 1.NHCOCH3
i)POCl3/DMF, 0 0C
ii) 80-90 0C, 5-6 h
N Cl
CHO
R
 1a-1c
R
  2a-2c
R = 2a: H; 2b: Br; 2c: NO2
Figure 1 Synthesis of compounds 2a–2c.
Table 1 Characteristic data for compounds 2a–2c.
Compound code Mol. formula M. W.
2a C10H6ClNO 191.1
2b C10H5BrClNO 268.92
2c C10H5ClN2O3 236.61
a Uncorrected.
b Solvent system: chloroform:ethanol (3:2).2.1.2. Step 2: synthesis of 2-chloroquinoline chalcones [2]
In a round bottom ﬂask equipped with sealed mechanical
stirrer, 40% sodium hydroxide solution and 15–20 ml metha-
nol were stirred in an ice-bath. Then compounds 2a–2c
(1 mol) and substituted acetophenones (1 mol) were added into
the above mixture and stirred for 24 h at room temperature. At
the end of the period, the reaction mixture was poured in ice
cold water, neutralized with dilute hydrochloric acid and the
resultant solid was ﬁltered, dried to give titled compounds
3a–3f. Scheme of synthesis of 2-chloroquinoline chalcones is
described in Fig. 2 and their characterization data in Table 2.
2.1.3. Step 3: synthesis of 2-chloroquinoline pyrazole derivatives
[4]
A mixture of compounds 3a–3f (1.0 mmol), hydrazine hydrate
(1.3 mmol) and AcOH (10 ml) was placed into an open Pyrex-
glass vessel. The above mixtures were subjected to microwave
irradiation with magnetic stirring for 5–7 min and with a max-
imum power of 300 W. Reaction progress was monitored by
TLC and the reaction mixture was poured in ice cold water.
The precipitate formed was ﬁltered off and recrystallized from
ethanol to yield MB-A to MB-BB. Scheme of synthesis of
2-chloroquinoline pyrazole derivatives is described in Fig. 3
and their characterization data in Table 3.
2.2. Spectral characterizations of synthesized compounds MB A
–BB are given below
2.2.1. MB-A: 1-(5-(2-chloroquinolin-3-yl)-3-phenyl-1H-
pyrazol-1-yl)ethanone
IR (KBr): v cm1 (C‚O) 1677.77, (C–H, Ar) 3061.44, (C‚N)
1594.84, (C–Cl) 780.17. 1H NMR (300 MHz CDCl3) d: 7.56–
8.37 (s, 5H, Quinoline), 7.20–7.48 (s, 5H, aromatic), 4.18 (s,
1H, pyrazole), 2.53 (s, 1H, CH3).
2.2.2. MB-Br: 1-(3-(4-bromophenyl)-5-(2-chloroquinolin-3-yl)-
1H-pyrazol-1-yl)ethanone
IR (KBr): v cm1 (C‚O) 1681.82, (C–H, Ar) 2922.50, (C‚N)
1582.31, (C–Br) 807.06, (C–Cl) 756.92. 1H NMR (300 MHz
CDCl3) d: 8.51 (s, 1H, Quinoline), 8.05 (s, 1H, Quinoline),
7.43–7.68 (s, 3H, Quinoline), 7.37–7.49 (s, 4H, aromatic),
4.30 (s, 1H, pyrazole), 2.25 (s, 1H, CH3). MS: m/z 450.15
(M+Na)+.
2.2.3. MB-F: 1-(5-(2-chloroquinolin-3-yl)-3-(4-ﬂuorophenyl)-
1H-pyrazol-1-yl)ethanone
IR (KBr): v cm1 (C‚O) 1681.62, (C–H) 3071.09, (C‚N)
1594.84, (C–F) 1236.15, (C–Cl) 756.92. 1H NMR (300 MHz
CDCl3) d: 8.73 (s, 1H, Quinoline), 8.26 (s, 1H, Quinoline),
7.43–7.75 (s,3H, quinoline), 7.49–7.68 (s,2H, aromatic), 7.13% Yield m. p. (C)a Rfb value
63 125–127 0.69
55 164–166 0.52
60 212–215 0.48
N Cl
CHO
CH3
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O
Ethanol, 30% NaOH, 
24 h stirring, rt N Cl
O
R'
2a-2c 3a-3f
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Compound 
   code R            R'
3a            H              H 
3b            H              Br 
3c            H              F 
3d            H              NH2
3e            NO2          Br 
3f             Br               Br
Figure 2 Synthesis of compounds 3a–3f.
Table 2 Characteristic data for compounds 3a–3f.
Compound code Mol. formula M. W. % Yield m. p. (C)a Rfb value
3a C18H12ClNO 293.1 78 132–140 0.65
3b C18H11BrClNO 372.48 69 223–226 0.59
3c C18H11ClFNO 331.79 71 210–215 0.61
3d C18H13ClN2O 308.56 81 157–161 0.68
3e C18H10BrClN2O3 417.36 67 248–250 0.58
3f C18H10Br2ClNO 451.54 64 198–203 0.60
a Uncorrected.
b Solvent system: n-hexane:ethyl acetate (3:2).
N Cl
O
R'
i) Glacial acetic acid, NH2-NH2 .H2O
ii) MW, 300 W, 5-7 min
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Figure 3 Synthesis of compounds MB-A–MBBB.
Table 3 Characteristic data for compounds MB-A to MB-BB.
Compound code Substituent Mol. formula M. W. % Yield m. p.a (0C) Rf
b value
R R0
MB-A H H C20H14ClON3 347.08 72 180–183 0.63
MB-Br Br H C20H13BrClON3 426.69 76 160–162 0.72
MB-F F H C20H13ClFON3 365.07 78 186–188 0.68
MB-N NH2 H C20H15ClON4 362.81 80 192–194 0.64
MB-BN NO2 Br C20H12BrClO3N4 471.69 81 182–186 0.59
MB-BB Br Br C20H12Br2ClON3 505.59 85 133–135 0.78
a Uncorrected.
b Solvent system: n-hexane:ethyl acetate (4:1).
Synthesis and biological evaluation of 1-(5-(2-chloroquinolin-3-yl)-3-phenyl-1H-pyrazol-1-yl)ethanone 657
Table 4 MIC values (lg/ml) against S. aureus, B. subtilis,
E. coli.
Compound code S. aureus B. subtilis E. coli
MB-A 200 54 43
MB-Br 213 103 77
MB-F 245 82 93
MB-N 225 44 87
MB-BN 246 108 97
MB-BB 289 104 96
Gatiﬂoxacin 32.5 30 28.5
Table 5 MIC values (lg/ml) against A. fumigatus, P. notatum.
Compound code A. fumigatus P. notatum
MB-A 77 57
MB-Br 98 102
MB-F 95 66
MB-N 48 46
MB-BN 89 93
MB-BB 96 113
Fluconazole 32.5 30.5
658 P.B. Miniyar et al.(s, 2H, aromatic), 5.02 (s, 1H, pyrazole), 2.65 (s, 1H, CH3).
MS: m/z 388.23 (M+Na)+.
2.2.4. MB-N: 1-(3-(4-aminophenyl)-5-(2-chloroquinolin-3-yl)-
1H-pyrazol-1-yl)ethanone
IR (KBr): v cm1 (C‚O) 1670.05, (N–H) 3341.07, (C–H)
3021.26, (C‚N) 1559.17, (C–Cl) 780.78. 1H NMR
(300 MHz CDCl3) d: 8.51 (s, 1H, Quinoline), 8.05 (s, 1H,
Quinoline), 7.57–7.59 (s, 2H, quinoline), 7.43–7.70 (s,3H,quin-
oline), 7.53 (s, 2H, aromatic), 6.52 (s, 2H, aromatic), 4.85 (s,
1H, pyrazole), 4.23(s, 2H,aromatic amine), 2.78 (s, 1H, CH3).
2.2.5. MB-BN: 1-(3-(4-bromophenyl)-5-(2-chloro-7-
nitroquinolin-3-yl)-1H-pyrazol-1-yl)ethanone
IR (KBr): v cm1(C‚O) 1681.62, (C–H) 2922.50, (C‚N)
1582.31, (C–NO2) 1397.17, (C–Br) 807.06, (C–Cl) 756.92.
1H
NMR (300 MHz CDCl3) d: 9.72 (s, 1H, NO2), 7.56–8.37 (s,
3H, Quinoline), 7.12–7.36 (s, 2H, aromatic), 7.46–7.51(s, 2H,
aromatic), 4.25 (s, 1H, pyrazole), 2.23 (s, 1H, CH3).
2.2.6. MB-BB: 1-(5-(7-bromo-2-chloroquinolin-3-yl)-3-(4-
bromophenyl)-1H-pyrazol-1-yl)ethanone
IR (KBr): v cm1(C‚O) 1666.2, (C–H) 3059.51, (C‚N)
1590.21, (C–Br) 840.81, (C–Cl) 750.17. 1H NMR (300 MHz
CDCl3) d: 8.43 (s, 1H, Quinoline), 8.28 (s, 1H, Quinoline),
7.57–7.59 (s, 2H, quinoline), 7.37 (s, 2H, aromatic), 7.49 (s,
2H, aromatic), 4.89 (s, 1H, pyrazole), 2.53 (s, 1H, CH3).3. Results and discussion
3.1. Chemistry
Cyclization of chalcones (3a–3f) with hydrazine hydrate by
using the microwave irradiation method to give various chlo-
roquinoline substituted pyrazole is described in Fig. 3. From
the IR spectra, it was observed that functional groups present
in the molecule appeared at their characteristic frequency.
C‚N str. between 1540 and 1590 cm1, C–Cl str. between
746 and 780 cm1, C‚O str. between 1666 and 1682 cm1
etc. The chemical shift (d) for 2-chloroquinoline hydrogen
was observed in the range of 7.56–8.37 ppm, d value for aro-
matic hydrogen was observed in the range of 7.20–7.48 ppm.
The m/e value was observed, e.g., in case of MB-Br and
MB-F at 450.15 (M+Na)+ and 388.23 (M+Na)+, respec-
tively. So, from the physical and spectral data, we can con-
clude that the desired compounds synthesized successfully.
3.2. Antibacterial and antifungal activity
All the synthesized compounds were screened for both antimi-
crobial and antifungal activity. Compounds were screened for
in vitro against two Gram positive strains Staphylococcus aur-
eus (S. aureus, NCIM 2079), Bacillus subtilis (B. subtilis,
NCIM 2711) and Gram negative Escherichia coli (E. coli,
NCIM 2685) bacteria for antibacterial and two fungal species
Aspergillus fumigatus (A. fumigatus, NCIM 535) and Penicil-
lium notatum (P. notatum, NCIM 745) for antifungal activity,
respectively using the broth microdilution method [14].
Minimum inhibitory concentration (MIC) was determined
and compared with standard drugs Gatiﬂoxacin for antibacte-rial activity (Table 4) and Fluconazole for antifungal activity
(Table 5).
From in vitro antifungal results, compound MB-N
(p-amino derivative) was found to have signiﬁcant activity as
compared to reference standard Fluconazole against A. fumig-
atus and P. Notatum, while derivative MB-A (acetophenone
derivative), MB-F (para-ﬂuro derivative) having moderate
activity as that of standard against P. notatum. The com-
pounds MB-Br, MB-BN and MB-BB showed least activity
against both the fungal strains (Fig. 4). So, from this study it
can be concluded that the electron-donating group i.e., (p-ami-
no) on the phenyl ring is contributing positively for the anti-
fungal activity whereas the unsubstituted phenyl ring as well
as the electron-withdrawing group are able to maintain the
moderate antifungal activity. Fluro substituted compound
(MB-F) having high electronegativity is showing moderate
activity as compared to bromo substitution (MB-Br) on the
phenyl ring.
In case of anti-bacterial activity, all the tested derivatives
showed least activity against S. aureus with MIC in the range
of 200–250 lg/ml. In case of B. subtilis and E. coli derivative
MB-A was found to have good activity which is 1–2 folds less
than the standard drug Gatiﬂoxacin while compound MB-N
showed signiﬁcant activity against B. subtilis. All other com-
pounds MB-Br, MB-F, MB-BN and MB-BB showed least
activity against B. subtilis and E. coli (Fig. 4). Thus from the
obtained antibacterial activity data we can conclude that com-
pounds with the unsubstituted phenyl ring (MB-A) were active
against gram negative as well as gram positive bacteria
whereas compounds with electron-donating group substituent
(MB-N) on the phenyl ring were active against B. subtilis.
Compounds with both electron-withdrawing and electron-
donating groups on the phenyl ring resulted in decreased
activity.
As far as quinoline nucleus is considered for all the synthe-
sized compounds, substitution at 7-position with the electron-
withdrawing group (MB-BN and MB-BB) results in poor
Figure 4 MIC of synthesized compounds in comparison with standard against different microbial strains.
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tion at 2-position was a key factor for both antibacterial as
well as antifungal activities.
4. Conclusion
A series of 2-chloroquinolines condensed with pyrazole nu-
cleus have been synthesized and evaluated for antibacterial
and antifungal activity. The compound MB-N was found to
be having moderate activity against A. fumigatus and P. nota-
tum, whereas compounds MB-A and MB-F were found active
against P. notatum. As far as antibacterial activity is concerned
compoundMB-A showed good activity against B. subtillis and
E. coli whereas compound MB-N has promising activity only
against B. subtillis. All the synthesized compounds showed
very poor activity against S. aureus.
So, the results obtained from antibacterial and antifungal
activities are more promising as the compounds showed signif-
icant activity as compared to standard or marketed drugs,
Gatiﬂoxaicn and Fluconazole. These results can be used fur-
ther to design and develop novel antimicrobial agents.Acknowledgement
The authors thank Dr. K.G. Bothara, Principal, Sinhgad Insti-
tute of Pharmacy, Narhe, Pune for providing research facility.
The authors also thank the University of Pune for 1H NMR
and I.I.C.B., Calcutta for Mass spectral analysis.
References
[1] W.A. Denny, W.R. Wilson, D.C. Ware, D.J. Atwell, J.B.
Milbank, R.J. Stevenson, U.S Patent 7064117 (2006).
[2] J.N. Dominguez, C. Leon, J. Rodrigues, N.G. Dominguez, J.
Gut, P.J. Rosenthal, Synthesis of chlorovinyl sulfones as
structural analogs of chalcones and their antiplasmodial
activities, Eur. J. Med. Chem. 44 (2009) 1457–1462.
[3] S. Eswaran, A.S. Adhikari, N.S. Shetty, Synthesis and
antimicrobial activities of novel quinoline derivatives carrying
1,2,4-triazole moiety, Eur. J. Med. Chem. 44 (2009) 4637–4647.
[4] B. Insuasty, A. Tigreros, F. Orozco, J. Quiroga, R. Abonı´a, M.
Nogueras, A. Sanchez, J. Cobo, Synthesis of novel pyrazolic
analogues of chalcones and their 3-aryl-4-(3-aryl-4,5-dihydro-1H-pyrazol-5-yl)-1-phenyl-1H-pyrazole derivatives as potential
antitumor agents, Bioorg. Med. Chem. 18 (2010) 4965–4974.
[5] M. Johnson, B. Younglove, L. Lee, R. Leblanc, H. Holt, P.
Hills, et al, Design, synthesis, and biological testing of
pyrazoline derivatives of combretastatin-A4, Bioorg. Med.
Chem. Lett. 17 (2007) 5897–5901.
[6] P.A. Leatham, H.A. Bird, V. Wright, D. Seymour, A.
Gordon, A double blind study of antrafenine, naproxen and
placebo in osteoarthrosis, Eur. J. Rheumatol. Inﬂamm. 6
(1983) 209–211.
[7] J.M. Lilienkampf, B.Y. Wan, S.G. Wang, A.P. Franzblau,
Structure–activity relationships for a series of quinoline-based
compounds active against replicating and nonreplicating
Mycobacterium tuberculosis, J. Med. Chem. 52 (2009) 2109–
2118.
[8] A. Loupy, A. Petit, J. Hamelin, F. Texier-Boullet, P. Jacquault,
D. Mathe, New solvent free organic synthesis using focused
microwaves, Synthesis (1998) 1213–1217.
[9] M.P. Maguire, K.R. Sheets, K. McVety, A.P. Spada, A.
Zilberstein, A new series of PDGF receptor tyrosine kinase
inhibitors: 3-substituted quinoline derivatives, J. Med. Chem. 37
(1994) 2129–2137.
[10] A. Mahamoud, J. Chevalier, A. Davin-Regli, J. Barbe, P. Jean-
Marie, Quinoline derivatives as promising inhibitors of
antibiotic efﬂux pump in multidrug resistant Enterobacter
aerogenes isolates, Curr. Drug Targets 7 (2006) 843–847.
[11] M.C. McManus, Mechanisms of bacterial resistance to
antimicrobial agents, Am. J. Health Syst. Pharm. 54 (1997)
1420–1433.
[12] N. Muruganantham, R. Sivakumar, N. Anbalagan, V.
Gunasekaran, J.T. Leonard, Synthesis, anticonvulsant and
antihypertensive activities of 8-substituted quinoline
derivatives, Biol. Pharm. Bull. 27 (2004) 1683–1687.
[13] P. Nasveld, S. Kitchener, Treatment of acute vivax malaria with
tafenoquine, Trans. R. Soc. Trop. Med. Hyg. 99 (2005) 2–5.
[14] A. Rattan, Antimicrob. Lab. Med. B, Churchill Livingstone,
New Delhi, 2005, pp. 85–90, Chapter 5.
[15] M.V. Reddy, V.K. Bila, V.R. Pallela, M.R. Mallireddigari, R.
Boominathan, J.L. Gabriel, Design, synthesis, and biological
evaluation of 1-(4-sulfamylphenyl)-3-triﬂuoromethyl-5-indolyl
pyrazolines as cyclooxygenase-2 (COX-2) and lipoxygenase
(LOX) inhibitors, Bioorg. Med. Chem. 16 (2008) 3907–3916.
[16] N.M. Shah, M.P. Patel, R.G. Patel, New N-arylamino
biquinoline derivatives: synthesis, antimicrobial,
antituberculosis, and antimalarial evaluation, Eur. J. Med.
Chem. 54 (2012) 239–247.
[17] Y.M. Shahar, M.A. Bakht, A.A. Siddiqui, M.M. Abdullah, C.E.
De, Synthesis and evaluation of in vitro antiviral activity of
660 P.B. Miniyar et al.novel phenoxy acetic acid derivatives, J. Enzyme Inhib. Med.
Chem. 24 (2009) 876–882.
[18] M. Shaharyar, A.A. Siddiqui, M.A. Ali, D. Sriram, P.
Yogeeswari, Synthesis and in vitro antimycobacterial activity
of N1-nicotinoyl-3-(40-hydroxy-30-methyl phenyl)-5-
[(sub)phenyl]-2-pyrazolines, Bioorg. Med. Chem. Lett. 13
(2006) 2213–2220.
[19] L. Strekowski, J.L. Mokrosz, V.A. Honkan, A.M. Czarny, T.
Cegla, S.E. Patterson, R.L. Wydra, R.F. Schinazi, Synthesis and
quantitative structure-activity relationship analysis of 2-(aryl or
heteroaryl)quinolin-4-amines, a new class of anti-HIV-1 agents,
J. Med. Chem. 34 (1991) 1739–1746.
[20] K. Tanaka, F. Toda, Solvent-free organic synthesis, Chem. Rev.
100 (2000) 1025–1074.[21] W.D.Wilson,M. Zhao, S.E. Patterson, R.L.Wydra, L. Janda, L.
Strekowski, Design of RNA interactive anti-HIV agents: unfused
aromatic intercalators, Med. Chem. Res. 2 (1992) 102–110.
[22] D. Zampieri, M.G. Mamolo, E. Laurii, G. Scialino, E. Banﬁ,
Antifungal and antimycobacterial activity of 1-(3,5-diaryl-4,5-
dihydro-1H-pyrazol-4-yl)-1H-imidazole derivatives, Bioorg.
Med. Chem. 16 (2008) 4516–4522.
[23] B.S. Furniss, A.J. Hannaford, P.W.G. Smith, A.R. Tatchell, in:
Vogel’s Textbook of Practical Organic Chemistry 5th ed., CBS
Publishers, New Delhi, pp 919.
[24] O. Meth-Cohn, B. Narine, B. Tarnowski, A versatile new
synthesis of quinolines and related fused pyridines, Part 5. The
synthesis of 2-chloroquinoline-3- carbaldehydes, J. Chem. Soc.
Perkin Trans. 1 (1981) 1520–1530.
